{
  "ticker": "BUB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958479",
  "id": "02958479",
  "pages": 1,
  "price_sensitive": true,
  "date": "20250616",
  "time": "0826",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krsc45vdzdpn.pdf",
  "summary": "- **Key Milestone**: Bubs Australia submitted its New Infant Formula Submission (NIFS) to the US FDA for three infant milk formulas (goat, grass-fed, and essential), a critical step for permanent US market access.  \n- **Regulatory Progress**: FDA review expected to commence immediately; formal approval decision anticipated by end of calendar year 2025.  \n- **Market Context**: Bubs is one of only eight companies operating under FDA\u2019s \"Enforcement Discretion\" for infant formula in the US, its largest market.  \n- **Clinical Trial Completion**: Enrollment of 478 infants in US clinical trial completed (largest single trial of its kind), supporting NIFS submission.  \n\n*No material financial, trading, or capital structure impacts disclosed.*",
  "usage": {
    "prompt_tokens": 889,
    "completion_tokens": 158,
    "total_tokens": 1047,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:31:50.298190"
}